Evidence map›Paper›PMID 26148204›Full record

Trial reportPharmacogenetics and genomics2015

Genomewide association study of tenofovir pharmacokinetics and creatinine clearance in AIDS Clinical Trials Group protocol A5202.

Valentine Wanga, Charles Venuto, Gene D Morse, Edward P Acosta, Eric S Daar, David W Haas, Chun Li, Bryan E Shepherd

Open access · greenAbstract readClinical Trial, Phase IIIRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Pharmacogenetics and genomics, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.6field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 18 citations in OpenAlex.

  1. Trial
  2. Article
  3. Understanding Cisplatin Pharmacokinetics and Toxicodynamics to Predict and Prevent Kidney Injury.The Journal of pharmacology and experimental therapeutics · 2024
    Review
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. Genetic susceptibility to infectious diseases: Current status and future perspectives from genome-wide approaches.Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases · 2018
    Review
  10. Article
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 2 countries.

Valentine WangaaDepartments of Biostatistics bDepartment of Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee cUniversity of Rochester Medical Center, Center for Human Experimental Therapeutics, Rochester dDepartment of Pharmaceutical Sciences, University at Buffalo, SUNY, Buffalo, New York eDepartment of Pharmacology and Toxicology, University of Alabama at Birmingham, School of Medicine, Birmingham, Alabama fDepartment of Medicine, Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, California gCase Western Reserve University, Department of Epidemiology and Biostatistics, Cleveland, Ohio, USA.
Charles Venuto
Gene D Morse
Edward P Acosta
Eric S Daar
David W Haas
Chun Li
Bryan E Shepherd
PharmacoGenetics (China) · CNGTx (United States) · US

Funding

Leadership and Operations Center (LOC), AIDS Clinical Trials Group (ACTG); LOC 1/UM1AI068636 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Joseph J Eron, RAJESH T GANDHI · 2011 to 2026
$1073.1M
Statistical and Data Management Center (SDMC), AIDS Clinical Trials Group (ACTG)UM1AI068634 · NIAID · HARVARD UNIVERSITY D/B/A HARVARD SCHOOL OF PUBLIC HEALTH · PI Marlene Ann Cooper, Michael David Hughes · 2011 to 2026
$246.6M
WOMEN'S HEALTH AGENDAU01AI038858 · NIAID · SOCIAL AND SCIENTIFIC SYSTEMS, INC. · PI BENSON, CONSTANCE ANN · 1996 to 2008
$157.5M
AIDS Clinical Trials Group NetworkU01AI068636 · NIAID · SOCIAL AND SCIENTIFIC SYSTEMS, INC. · PI KURITZKES, DANIEL R. · 2006 to 2010
$147.1M
Validation, CLIA and Qualification (VQC): Enhancing the RS ratio as a tool for AIDS Clinical Trial Group (ACTG) tuberculosis trialsUM1AI106701 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Grace M Aldrovandi · 2014 to 2026
$116.8M
Virus & Reservoirs CoreP30AI045008 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI DAVID S METZGER · 1999 to 2026
$78.6M
STATISTICAL AND DATA MANAGEMENT CENTERU01AI038855 · NIAID · HARVARD UNIVERSITY (SCH OF PUBLIC HLTH) · PI HUGHES, MICHAEL DAVID · 1996 to 2006
$78.1M
Virology, Immunology, and Microbiology CoreP30AI050410 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI DAVID M. MARGOLIS · 2001 to 2026
$76.9M
Virology and Molecular Biomarkers CoreP30AI050409 · NIAID · EMORY UNIVERSITY · PI Ann M Chahroudi, Colleen F Kelley · 2002 to 2026
$74.0M
Statistical and Data Management Center for the AIDS Clinical Trials GroupU01AI068634 · NIAID · HARVARD SCHOOL OF PUBLIC HEALTH · PI HUGHES, MICHAEL DAVID · 2006 to 2010
$71.9M
University of North Carolina Global HIV Prevention and Treatment Clinical Trials Unit 2024 SupplementUM1AI069423 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Joseph J Eron, MINA CHRISTINE HOSSEINIPOUR · 2012 to 2026
$71.8M
CTSA INFRASTRUCTURE FOR PEDIATRIC RESEARCHUL1RR024156 · NCRR · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI GINSBERG, HENRY N · 2006 to 2011
$53.0M
NCATS NIH HHS TR-000445NCATS NIH HHS UL1 TR000445NCATS NIH HHS UL1 TR000457NCATS NIH HHS UL1 TR001082NCATS NIH HHS UL1 TR001417NCRR NIH HHS M01 RR000046NCRR NIH HHS M01 RR000051NCRR NIH HHS RR-00046NCRR NIH HHS RR-00051NCRR NIH HHS RR-024156NCRR NIH HHS RR-024160NCRR NIH HHS RR024160NCRR NIH HHS RR-024996NCRR NIH HHS RR-025747NCRR NIH HHS RR-025777NCRR NIH HHS UL1 RR024156NCRR NIH HHS UL1 RR024160NCRR NIH HHS UL1 RR024975NCRR NIH HHS UL1 RR024996NCRR NIH HHS UL1 RR025747NCRR NIH HHS UL1 RR025777NIAID NIH HHS AI-025859NIAID NIH HHS AI-027658NIAID NIH HHS AI-027661NIAID NIH HHS AI-027675NIAID NIH HHS AI-032782NIAID NIH HHS AI-034853NIAID NIH HHS AI-038855NIAID NIH HHS AI-038858NIAID NIH HHS AI-045008NIAID NIH HHS AI-046370NIAID NIH HHS AI-046376NIAID NIH HHS AI-050409NIAID NIH HHS AI050410NIAID NIH HHS AI-054907NIAID NIH HHS AI-054999NIAID NIH HHS AI-058740NIAID NIH HHS AI-068634NIAID NIH HHS AI-068636NIAID NIH HHS AI-069415NIAID NIH HHS AI-069418NIAID NIH HHS AI-069419NIAID NIH HHS AI-069423NIAID NIH HHS AI-069424NIAID NIH HHS AI-069428NIAID NIH HHS AI-069432NIAID NIH HHS AI-069434NIAID NIH HHS AI-069439NIAID NIH HHS AI-069447NIAID NIH HHS AI-069465NIAID NIH HHS AI-069467NIAID NIH HHS AI-069470NIAID NIH HHS AI-069471NIAID NIH HHS AI-069472NIAID NIH HHS AI-069474NIAID NIH HHS AI-069477NIAID NIH HHS AI-069484NIAID NIH HHS AI-069494NIAID NIH HHS AI-069495NIAID NIH HHS AI-069501NIAID NIH HHS AI-069502NIAID NIH HHS AI-069511NIAID NIH HHS AI-069513NIAID NIH HHS AI-069532NIAID NIH HHS AI-069556NIAID NIH HHS AI-072626NIAID NIH HHS AI-073961NIAID NIH HHS AI-077505NIAID NIH HHS AI-093234NIAID NIH HHS AI-27666NIAID NIH HHS AI-69450NIAID NIH HHS P30 AI045008NIAID NIH HHS P30 AI050409NIAID NIH HHS P30 AI050410NIAID NIH HHS P30 AI054907NIAID NIH HHS P30 AI054999NIAID NIH HHS P30 AI073961NIAID NIH HHS R01 AI058740NIAID NIH HHS R01 AI077505NIAID NIH HHS R01 AI093234NIAID NIH HHS U01 AI025859NIAID NIH HHS U01 AI027658NIAID NIH HHS U01 AI027661NIAID NIH HHS U01 AI027666NIAID NIH HHS U01 AI027675NIAID NIH HHS U01 AI032782NIAID NIH HHS U01 AI034853NIAID NIH HHS U01 AI038855NIAID NIH HHS U01 AI038858NIAID NIH HHS U01 AI046370NIAID NIH HHS U01 AI046376NIAID NIH HHS U01 AI068634NIAID NIH HHS U01 AI068636NIAID NIH HHS U01AI068636NIAID NIH HHS U01 AI069415NIAID NIH HHS U01 AI069418NIAID NIH HHS U01 AI069419NIAID NIH HHS U01 AI069423NIAID NIH HHS U01 AI069424NIAID NIH HHS U01 AI069428NIAID NIH HHS U01 AI069432NIAID NIH HHS U01 AI069434NIAID NIH HHS U01 AI069439NIAID NIH HHS U01 AI069447NIAID NIH HHS U01 AI069450NIAID NIH HHS U01 AI069452NIAID NIH HHS U01 AI069465NIAID NIH HHS U01 AI069467NIAID NIH HHS U01 AI069470NIAID NIH HHS U01 AI069471NIAID NIH HHS U01 AI069472NIAID NIH HHS U01 AI069474NIAID NIH HHS U01 AI069477NIAID NIH HHS U01 AI069484NIAID NIH HHS U01 AI069494NIAID NIH HHS U01 AI069495NIAID NIH HHS U01 AI069501NIAID NIH HHS U01 AI069502NIAID NIH HHS U01 AI069511NIAID NIH HHS U01 AI069513NIAID NIH HHS U01 AI069532NIAID NIH HHS U01 AI069556NIAID NIH HHS UM1 AI068634NIAID NIH HHS UM1 AI068636NIAID NIH HHS UM1 AI069415NIAID NIH HHS UM1 AI069418NIAID NIH HHS UM1 AI069419NIAID NIH HHS UM1 AI069423NIAID NIH HHS UM1 AI069424NIAID NIH HHS UM1 AI069428NIAID NIH HHS UM1 AI069432NIAID NIH HHS UM1 AI069434NIAID NIH HHS UM1 AI069439NIAID NIH HHS UM1 AI069447NIAID NIH HHS UM1 AI069450NIAID NIH HHS UM1 AI069452NIAID NIH HHS UM1 AI069465NIAID NIH HHS UM1 AI069467NIAID NIH HHS UM1 AI069470NIAID NIH HHS UM1 AI069471NIAID NIH HHS UM1 AI069472NIAID NIH HHS UM1 AI069474NIAID NIH HHS UM1 AI069477NIAID NIH HHS UM1 AI069484NIAID NIH HHS UM1 AI069494NIAID NIH HHS UM1 AI069495NIAID NIH HHS UM1 AI069496NIAID NIH HHS UM1 AI069501NIAID NIH HHS UM1 AI069502NIAID NIH HHS UM1 AI069511NIAID NIH HHS UM1 AI069513NIAID NIH HHS UM1 AI069532NIAID NIH HHS UM1 AI069556NIAID NIH HHS UM1 AI106701NINDS NIH HHS T32 NS007338
6 · The paper itself

Abstract

backgroundTenofovir disoproxil fumarate (TDF) causes kidney toxicity in some patients. We carried out genomewide analyses to identify associations with plasma tenofovir clearance and change in creatinine clearance (CrCl) during the first 6 months after initiating therapy among patients randomized to TDF/emtricitabine-containing regimens in AIDS Clinical Trials Group protocol A5202.

methodsPharmacokinetic analyses involved 501 patients randomized to the tenofovir arm. CrCl analyses involved 1096 patients, including 548 controls randomized to abacavir-containing regimens. All had been randomized to also receive atazanavir/ritonavir or efavirenz. Multivariable linear regression and generalized least squares models were used to test for associations between polymorphisms and tenofovir clearance and CrCl change, with Bonferroni correction. Planned subanalyses considered candidate genes and polymorphisms.

resultsMedian CrCl at baseline was 116 ml/min (interquartile range 99.8-135.5). The median change in CrCl after 6 months was -0.5 ml/min (-10.7 to +10.8) and 2.2 (interquartile range -9.9 to +13.2) in tenofovir and abacavir arms, respectively. In genomewide analyses SLC17A1 rs12662869 was found to be associated with an increase in tenofovir clearance (P=7.1×10). In candidate gene analysis for tenofovir clearance, most polymorphisms evaluated were in ABCC4. In the ABCC4 region, the lowest P-value was for CLDN10 rs12866697 (P=1.4×10). Among African Americans, SLC22A2 rs3127573 was associated with a greater 6-month CrCl increase in the tenofovir arm after correcting for multiple comparisons (P=3.3×10).

conclusionAmong patients randomized to receive TDF/emtricitabine in A5202, there were no significant genomewide associations with change in CrCl. This study did not replicate polymorphisms previously implicated in tenofovir-associated renal injury.

Indexed as

AbacavirAcquired Immunodeficiency SyndromeAdultAlkynesAnti-HIV AgentsBenzoxazinesCreatinineCyclopropanesDideoxynucleosidesFemaleGenome-Wide Association StudyHumansMalePolymorphism, Single NucleotideRitonavirTenofovirAbacavirAlkynesAnti-HIV AgentsBenzoxazinesCreatinineCyclopropanesDideoxynucleosidesefavirenzRitonavirTenofovir

Identifiers

PMID26148204
PMCPMC4522226
OpenAlexW2410490377

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.